Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055146 · ClinicalTrials.gov registry record · Phase 2
Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)
A Phase 2 study of Leukemia, Lymphocytic, Chronic, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 14
- Study locations
NCT00055146 is a Phase 2 study of Leukemia, Lymphocytic, Chronic that has completed, run by Eisai. The registered enrollment target is 41 participants. The trial reports 14 study locations across 11 states.
The verdict
NCT00055146, a Phase 2 study of Leukemia, Lymphocytic, Chronic, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of ONTAK in previously treated patients with chronic lymphocytic leukemia (CLL)
Conditions Studied
Interventions
- DRUG ONTAK
Study Locations (14)
California
- Pacific Coast Hematology/Oncology Medical Group, Inc. - Fountain Valley
- UCSD School of Medicine - La Jolla
Other
- Montecaseros - Mendoza
- Oncology Day Unit, Frankston Hospital - Frankston
São Paulo
- Hospital de Cancer de Barretos - Fundacao Pio XII - Barretos
- Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo - São Paulo
Illinois
- Rush-Presbyterian St. Luke's Cancer Center - Chicago
New York
- Weill Medical College of Cornell University/New York Presbyterian Hospital - New York
Texas
- University of Texas, M.D. Anderson Cancer Center - Houston
Victoria
- Peter MacCallum Cancer Institute - East Melbourne
Goiás
- Hospital Araujo Jorge - Associacao de Combate ao Cancer em Goias - Goiânia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2003-03 |
| Est. Completion | 2006-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00055146
The ClinicalTrials.gov registry entry for NCT00055146 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia, Lymphocytic, Chronic appearing as the primary indexed condition, and to 1 intervention - of which ONTAK is the first listed.
NCT00055146 reports 14 study locations spanning 11 distinct geographic areas - top geographies include California, Other, São Paulo.
Frequently Asked Questions
What is clinical trial NCT00055146 about?
NCT00055146 is a clinical study titled "Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)". The purpose of this study is to evaluate the safety and effectiveness of ONTAK in previously treated patients with chronic lymphocytic leukemia (CLL)
What is the current status of trial NCT00055146?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2003-03. Estimated completion is 2006-05.
What conditions does trial NCT00055146 study?
This clinical trial studies the following conditions: Leukemia, Lymphocytic, Chronic.
What interventions are being tested in trial NCT00055146?
The interventions under investigation include: ONTAK (DRUG).
Who is sponsoring clinical trial NCT00055146?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00055146 being conducted?
This trial has 14 study locations across California, Illinois, New York, Texas, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia, Lymphocytic, Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.